Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTP ICAP Regulatory News (TCAP)

Share Price Information for TP ICAP (TCAP)

Share Price is delayed by 15 minutes
Get Live Data
340.00    -1.40 (-0.41%)
Bid:
340.20
Ask:
340.40
Spread: 0.20 (0.059%)
Market Cap: £2.48b
TCAP Live PriceLast checked at - London Stock Exchange

Intraday TP ICAP Share Chart

Director Declaration

16 Nov 2018 15:42

RNS Number : 6692H
TP ICAP PLC
16 November 2018
 

TP ICAP PLC

 

16 November 2018

 

TP ICAP plc confirms regulatory approval of Nicolas Breteau

 

Following the appointment of Nicolas Breteau as Chief Executive on 10 July 2018, TP ICAP plc (the "Company") is pleased to confirm that on 14 November 2018 it received regulatory approval from the Financial Conduct Authority of Mr Breteau's appointment as Executive Director (CF1) at Tullet Prebon (Securities) Limited, ICAP Securities Limited and iSwap Euro Limited.

 

There are no other details that are required to be disclosed in respect of Mr Breteau's appointment under Paragraph 9.6.13 of the Listing Rules of the UK Listing Authority.

 

ENDS

 

Media enquiries:

 

Jamie Dunkley

Jamie.Dunkley@tpicap.com

+44 (0) 20 7200 7524

 

About TPICAP

TP ICAP brings together buyers and sellers in global financial, energy and commodities markets. It is the world's largest wholesale market intermediary, with a portfolio of businesses that provide broking services, data & analytics and market intelligence, trusted by clients around the world. We operate from offices in 31 countries, supporting award-winning brokers with market-leading technology.

www.tpicap.com

 

About Nicolas Breteau

Nicolas Breteau has extensive experience across the global broking industry. He joined Tullett Prebon as Chief Commercial Officer in 2016, and then moved to run TP ICAP's largest business, Global Broking.

Nicolas started his career in 1993 on the Listed Derivatives Exchange MATIF (later part of Euronext). From 1993 to 1998, he held several senior positions at the derivatives broker FIMAT, including Deputy CEO of the

Paris Office. He then moved to London as Head of Risk for EMEA, and subsequently became Deputy CEO then CEO of the FIMAT London Branch.

In 2005, Nicolas was promoted to CEO of EMEA, a position he consolidated after Newedge was formed through the merger of FIMAT with Calyon Financial in 2008. He was appointed Global Head of Sales and Front-Office in 2009 and became Chief Executive of Newedge Group in 2010. He moved from Newedge in 2014 following the sale of the company to Société Générale, and became Senior Managing Partner of a consulting firm, 99 Advisory.

Nicolas graduated from Ecole Superieure de Commerce de Bordeaux. He has been a director of several Boards including the Futures and Options Association (UK), Futures Industry Association (USA), Altura (Spain), Citic/Newedge (China) and has been the chairman of i-swap since February 2018.

He is a trustee at PSE For a Child's Smile UK, which helps deprived children in Cambodia.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RDNUNSVRWRAAAAA
Date   Source Headline
17th May 20235:05 pmRNSResult of AGM
17th May 20237:00 amRNSTrading Statement
13th Apr 202312:30 pmRNSHolding(s) in Company
5th Apr 20233:00 pmRNSDirector/PDMR Shareholding
4th Apr 202311:00 amRNSNotice of AGM and Committee Membership Changes
3rd Apr 20235:05 pmRNSDirector/PDMR Shareholding
29th Mar 20234:00 pmRNSHolding(s) in Company
23rd Mar 202311:00 amRNSDirector/PDMR Shareholding
22nd Mar 202311:00 amRNS2022 Annual Report and Accounts
14th Mar 20237:00 amRNSTP ICAP Group PLC - Final Results
8th Feb 20234:19 pmRNSChanges to Senior Independent Director
13th Dec 202210:00 amRNSHolding(s) in Company
6th Dec 20225:15 pmRNSHolding(s) in Company
1st Nov 20227:00 amRNSTrading Statement
27th Oct 20225:30 pmRNSHolding(s) in Company
25th Oct 20225:50 pmRNSHolding(s) in Company
13th Sep 20225:32 pmRNSHolding(s) in Company
10th Aug 20227:00 amRNSHalf-year Report
28th Jul 20225:22 pmRNSResult of External Audit Tender
30th Jun 20225:44 pmRNSHolding(s) in Company
27th May 20223:30 pmRNSDirector/PDMR Shareholding
11th May 20226:01 pmRNSResult of AGM
11th May 20227:00 amRNSTrading Statement
4th May 20224:27 pmRNSGrant of Options and Director/PDMR Shareholding
22nd Apr 20224:49 pmRNSHolding(s) in Company
11th Apr 20224:17 pmRNSHolding(s) in Company
5th Apr 202211:02 amRNSAnnual Financial Report
4th Apr 20224:03 pmRNSDirector/PDMR Shareholding
31st Mar 20226:03 pmRNSDirector/PDMR Shareholding
29th Mar 20225:44 pmRNSHolding(s) in Company
15th Mar 20227:00 amRNSFinal Results
11th Jan 202211:35 amRNSHolding(s) in Company
22nd Dec 20215:00 pmRNSAppointment of new director
13th Dec 20213:24 pmRNSDirector/PDMR Shareholding
12th Nov 20212:04 pmRNSShareholder meeting update and PDMR transactions
12th Nov 20211:57 pmRNSTotal Voting Rights
2nd Nov 20217:00 amRNSTrading update - three months ended 30/09/2021
11th Oct 20214:00 pmRNSDirector/PDMR Shareholding
11th Oct 20213:01 pmRNSParameta Solutions Investor Seminar
7th Oct 202110:40 amRNSDirector/PDMR Shareholding
20th Sep 20214:58 pmRNSDirector/PDMR Shareholding
8th Sep 20215:08 pmRNSDirector/PDMR Shareholding
7th Sep 20217:00 amRNSHalf-year Report
3rd Aug 20217:00 amRNSTrading Statement
22nd Jun 20214:36 pmRNSDirector/PDMR Shareholding
18th May 202111:20 amRNSDirector/PDMR Shareholding
12th May 20215:49 pmRNSResult of AGM
12th May 20217:00 amRNSTrading Statement
23rd Apr 20215:10 pmRNSGrant of Options and Director/PDMR Shareholding
6th Apr 20214:32 pmRNSDirector/PDMR Shareholding - Replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.